Rhumbline Advisers Sells 5,452 Shares of Annexon, Inc. $ANNX

Rhumbline Advisers reduced its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 3.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 136,400 shares of the company’s stock after selling 5,452 shares during the period. Rhumbline Advisers owned 0.12% of Annexon worth $263,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ANNX. Jane Street Group LLC boosted its holdings in shares of Annexon by 38.1% during the 4th quarter. Jane Street Group LLC now owns 92,371 shares of the company’s stock worth $474,000 after buying an additional 25,507 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Annexon during the 4th quarter worth $59,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Annexon by 6.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company’s stock worth $325,000 after buying an additional 4,092 shares during the period. Millennium Management LLC boosted its holdings in shares of Annexon by 114.3% during the 4th quarter. Millennium Management LLC now owns 155,676 shares of the company’s stock worth $799,000 after buying an additional 83,021 shares during the period. Finally, ProShare Advisors LLC raised its stake in Annexon by 80.1% during the 4th quarter. ProShare Advisors LLC now owns 32,548 shares of the company’s stock valued at $167,000 after purchasing an additional 14,475 shares during the last quarter.

Analyst Upgrades and Downgrades

ANNX has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Annexon in a report on Friday, August 15th. Zacks Research raised shares of Annexon from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Annexon has an average rating of “Moderate Buy” and a consensus target price of $12.50.

Annexon Stock Performance

Shares of ANNX stock opened at $2.79 on Friday. Annexon, Inc. has a 52-week low of $1.28 and a 52-week high of $7.85. The stock has a market cap of $306.59 million, a price-to-earnings ratio of -2.16 and a beta of 1.15. The firm has a fifty day moving average of $2.40 and a 200-day moving average of $2.24.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. On average, sell-side analysts predict that Annexon, Inc. will post -0.96 earnings per share for the current year.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.